Severe Persistent Cerebellar Dysfunction Complicating Cytosine Arabinoside Therapy
- 24 April 2009
- journal article
- case report
- Published by Wiley in Acta Medica Scandinavica
- Vol. 224 (2), 189-191
- https://doi.org/10.1111/j.0954-6820.1988.tb16760.x
Abstract
A case of persistent cerebellar dysfunction following high-dose cytosine arabinoside (Ara-C) treatment of acute myelogenous leukemia is reported. The symptoms developed after a cumulative dose of 24 g/m2, and 6 months after the start of symptoms, the signs of cerebellar damage were unchanged. The symptoms aggravated during a subsequent low-dose therapy with Ara-C, 15 mg twice daily. This supports the presumption that this adverse effect is caused by the cumulative dose rather than by high plasma concentrations.Keywords
This publication has 14 references indexed in Scilit:
- Phase I-II clinical and pharmacologic studies of high-dose cytosine arabinoside in refractory leukemiaAmerican Journal Of Medicine, 1986
- Treatment-Related LeukoencephalopathyMedicine, 1986
- Cerebellar dysfunction during high dose cytosine arabinoside therapy in a case of acute myelogenous leukaemiaScandinavian Journal of Haematology, 1986
- Central nervous system toxicity with high‐dose Ara‐CNeurology, 1985
- Acute cerebellar dysfunction with high-dose ARA-C therapyCancer, 1983
- Therapy of Secondary Acute Nonlymphocytic Leukemia with CytarabineNew England Journal of Medicine, 1983
- High Dose Cytosine Arabinoside in the Management of Refractory Acute LeukaemiaScandinavian Journal of Haematology, 1982
- Effect of schedule and combinations on clinical effectiveness of Ara-C in adult acute leukemiaMedical and Pediatric Oncology, 1982
- Central nervous system toxicity of high-dose systemic cytosine arabinosideCancer, 1981
- Cerebellar Degeneration With Hodgkin DiseaseArchives of Neurology, 1976